Phase 3 Trial Results Suggest Flortaucipir Tracer Agent Can Help Predict Alzheimer’s Diagnosis

Phase 3 Trial Results Suggest Flortaucipir Tracer Agent Can Help Predict Alzheimer’s Diagnosis
Flortaucipir, an investigational imaging agent, was able to efficiently detect Tau protein aggregates and related Alzheimer's disease brain changes, meeting both of its primary objectives in a Phase 3 trial. Results of the trial revealed that flortaucipir demonstrated great sensitivity in identifying tau-related damage and predicting Alzheimer's disease diagnosis. "These encouraging results are a major advance in our ability to image the pathology of Alzheimer's disease," Mark Mintun, MD, vice president of pain and neurodegeneration research and development at Eli Lilly and Company, said in a press release. Flortaucipir, also known as [F-18]T807 or 18F-AV-1451, is a radiolabeled positron emission tomography (PET) tracer agent being developed by Avid Radiopharmaceuticals, a wholly owned subsidiary of Lilly. It was designed to specifically detect abnormal Tau protein aggregates, which are important contributors to the development and progression of several neurological conditions, including Alzheimer’s disease. This investigational tracer has shown a 25 times higher selectivity for tau over beta-amyloid tangles, another type of toxic protein aggregate often present in Alzheimer’s disease. Compared with other tau-targeted tracers being developed, flortaucipir was more specific and efficient in determini
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *